Original Article
Hyaluronan coated cerium oxide nanoparticles modulate CD44 and reactive oxygen species expression in human fibroblasts
Megan S. Lord,
Brooke L. Farrugia,
Claudia M. Y. Yan,
James A. Vassie,
John M. Whitelock,
Corresponding Author
Megan S. Lord
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Correspondence to: M. Lord; e-mail: [email protected]Search for more papers by this authorBrooke L. Farrugia
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorClaudia M. Y. Yan
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorJames A. Vassie
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorJohn M. Whitelock
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorMegan S. Lord,
Brooke L. Farrugia,
Claudia M. Y. Yan,
James A. Vassie,
John M. Whitelock,
Corresponding Author
Megan S. Lord
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Correspondence to: M. Lord; e-mail: [email protected]Search for more papers by this authorBrooke L. Farrugia
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorClaudia M. Y. Yan
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorJames A. Vassie
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorJohn M. Whitelock
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052 Australia
Search for more papers by this authorAbstract
Cerium oxide nanoparticles are being widely explored for cell therapies. In this study, nanoceria was functionalized with hyaluronan (HA) using the organosilane linker, 3-aminopropyltriethoxysilane. HA-nanoceria was found to be cytocompatible and to reduce intracellular reactive oxygen species in human fibroblasts. The HA-nanoceria was found to colocalize with CD44 on the surface of the cells and once internalized traffic to the lysosomes, be degraded and induce markers of autophagy. These particles were also effective in reducing the cell surface expression of CD44. Together these data suggest that HA-nanoceria is a promising drug delivery material to target CD44-expressing cells through a variety of mechanisms. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1736–1746, 2016.
REFERENCES
- 1Lord MS, Tsoi B, Gunawan C, Teoh WY, Amal R, Whitelock JM. Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles. Biomaterials 2013; 34: 8808–8818.
- 2Karakoti AS, Monteiro-Riviere NA, Aggarwal R, Davis JP, Narayan RJ, Self WT, McGinnis J, Seal S. Nanoceria as antioxidant: Synthesis and biomedical applications. JOM 2008; 60: 33–37.
- 3Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009; 5: 2848–2856.
- 4Martin P, Leibovich SJ. Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol 2005; 15: 599–607.
- 5Zhao J, Castranova V. Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health B Crit Rev 2011; 14: 593–632.
- 6Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF. Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2: 544–568.
- 7Soltes L, Mendichi R, Kogan G, Schiller J, Stankovska M, Arnhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 2006; 7: 659–668.
- 8Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nano 2006; 1: 142–150.
- 9Tarnuzzer RW, Colon J, Patil S, Seal S. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett 2005; 5: 2573–2577.
- 10Wason MS, Colon J, Das S, Seal S, Turkson J, Zhao J, Baker CH. Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomed-Nanotechnol 2014; 9: 558–569.
- 11Asati A, Santra S, Kaittanis C, Perez JM. Surface-charge-dependent cell localisation and cytotoxicity of cerium oxide nanoparticles. ACS Nano 2010; 4: 5321–5331.
- 12Asati A, Santra S, Kaittanis C, Nath S, Perez JM. Oxidase-like activity of polymer-coated cerium oxide nanoparticles. Angew Chem. Int. Ed 2009; 48: 2308–2312.
- 13Karakoti AS, Singh S, Kumar A, Malinska M, Kuchibhatla SV, Wozniak K, Self WT, Seal S. PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc 2009; 131: 14144–5.
- 14Qi L, Fresnais J, Muller P, Theodoly O, Berret JF, Chapel JP. Interfacial activity of phosphonated-polyethylele glycol functionalized cerium oxide nanoparticles. Langmuir 2012; 28: 11448–11456.
- 15Ting SRS, Whitelock JM, Tomic R, Gunawan C, Teoh WY, Amal R, Lord MS. Cellular uptake and activity of heparin functionalised cerium oxide nanoparticles in monocytes. Biomaterials 2013; 34: 4377–4386.
- 16Vassie JA, Whitelock JM, Lord MS. Glycosaminoglycan functionalized nanoparticles exploit glycosaminoglycan functions. Methods Mol Biol 2015; 1229: 557–565.
- 17Chen WYJ, Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair Regen 1999; 7: 79–89.
- 18Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528–539.
- 19Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007; 23: 435–461.
- 20Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271–335.
- 21Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241–319.
- 22Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL, Rosada C. Expression of CD44 in human lung tumors. Cancer Res 1994; 54: 1381–1387.
- 23Acharya PS, KMajumdar S, Jacob M, Hayden J, Mrass P, Weninger W, Assoian RK, Pure E. Fibroblast migration is mediated by CD44-dependent TGFβ activation. J Cell Sci 2008; 121: 1393–1402.
- 24Marhaba R, Zöller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004; 35: 211–231.
- 25Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. CRC Cr Rev Cl Lab Sci 2002; 39: 527–579.
- 26Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S. Hyaluronan–CD44 interactions as potential targets for cancer therapy. Febs J 2011; 278: 1429–1443.
- 27Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014; 32: 145–156.
- 28Rivkin I, Cohen K, Koffler J, Melikhov D, Peer D, Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010; 31: 7106–7114.
- 29El-Dakdouki MH, Zhu DC, El-Boubbou K, Kamat M, Chen J, Li W, Huang X. Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. Biomacromolecules 2012; 13: 1144–1151.
- 30Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MG, Moghimi SM, et al. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 2011; 156: 231–238.
- 31Lord MS, Jung M, Teoh WY, Gunawan C, Vassie JA, Amal R, Whitelock JM. Cellular uptake and reactive oxygen species modulation of cerium oxide nanoparticles in human monocyte cell line U937. Biomaterials 2012; 33: 7915–7924.
- 32Melrose J, Numata Y, Ghosh P. Biotinylated hyaluronan: A versatile and highly sensitive probe capable of detecting nanogram levels of hyaluronan binding proteins (hyaladherins) on electroblots by a novel affinity detection procedure. Electrophoresis 1996; 17: 205–212.
- 33Busch W, Bastian S, Trahorsch U, Iwe M, Kühnel D, Meißner T, Springer A, Gelinsky M, Richter V, Ikonomidou C, et al. Internalisation of engineered nanoparticles into mammalian cells in vitro: Influence of cell type and particle properties. J Nanoparticle Res 2011; 13: 293–310.
- 34Melrose J, Smith S, Ghosh P, Taylor TK. Differential expression of proteoglycan epitopes and growth characteristics of intervertebral disc cells grown in alginate bead culture. Cells Tissues Org 2001; 168: 137–146.
- 35Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): Implications for cancer progression and treatment. Antioxid Redox Signal 2009; 11: 777–790.
- 36Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol 2008; 445: 77–88.
- 37Molina RM, Konduru NV, Jimenez RJ, Pytgiotakis G, Demokritou P, Wohlleben W, Brain JD. Bioavailability, distribution and clearance of tracheally instilled, gavaged or injected cerium dioxide nanoparticles and ionic cerium. Environ Sci Nano 2014; 1: 561–573.
- 38Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505–515.
- 39Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004; 377: 159–169.
- 40Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: Size matters. J Nanobiotechnol 2014; 12: 5–15.
- 41Simko M, Tischler S, Mattsson MO. Pooling and analysis of published in vitro data: A proof of concept study for the grouping of nanoparticles. Int J Mol Sci 2015; 16: 26211–26236.
- 42Pauloin T, Dutot M, Joly F, Warnet JM, Rat P. High molecular weight hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial corneal cells. Mol Vis 2009; 15: 577–583.
- 43Rees MD, Hawkins CL, Davies MJ. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem J 2004; 381: 175–184.
- 44Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med 1996; 21: 335–348.
- 45Contreras-Ruiz L, de la Fuente M, Parraga JE, Lopez-Garcia A, Fernandez I, Seijo B, Sanchez A, Calonge M, Diebold Y. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 2011; 17: 279–290.
- 46Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004; 6: 343–353.
- 47Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007; 3: 246–257.
- 48Stair-Nawy S, Csoka AB, Stern R. Hyaluronidase expression in human skin fibroblasts. Biochem Biophys Res Commun 1999; 266: 268–273.
- 49Hascall VC, Majors AK, De la Motte C, Evanko SP, Wang A, Drazba JA, Strong SA, Wight TN. Intracellular hyaluronan: A new frontier for inflammation? Biochim Biophys Acta 2004; 1673: 3–12.
- 50Culty M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992; 116: 1055–1062.
- 51Tammi R, Rilla K, MacCallum JPP, Hogg DK, MLuukkonen M, Hascall M, Tammi VCM. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem 2001; 276: 35111–35122.
- 52Okamoto I, Kawano Y, Murakami D, Sasyama T, Araki N, Miki T, Wong AJ, Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001; 155: 755–762.
- 53Bendall LJ, James A, Zannettino A, Simmons PJ, Gottlieb DJ, Bradstock KF. A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunol Cell Biol 2003; 81: 311–319.
- 54Zöller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254–267.
- 55Foster LC, Arkonae BM, Sibinga NES, Shi C, Perrella MA, Haber E. Regulation of CD44 gene expression by the proinflammatory cytokine interleukin-1β in vascular smooth muscle cells. J Biol Chem 1998; 273: 20341–20346.
- 56Zhang M, Wang MH, Singh RK, Wells A, Siegal GP. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem 1997; 272: 14139–14146.
- 57Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R, Shridhar V. Nanoceria: A rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS ONE 2013; 8: e54578.
- 58Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley EA, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundency. Proc Natl Acad Sci USA 2004; 101: 18081–18086.
- 59Wang A, de la Motte C, Lauer M, Hascall VC. Hyaluronan matrices in pathobiological processes. Febs J 2011; 278: 1412–1418.
Citing Literature
